Arvinas, Inc. (ARVN) – What Are Researchers Saying About This Stock?

Shares of Arvinas, Inc. (NASDAQ:ARVN) have been assigned a consensus rating of “Moderate Buy” from the ten analysts that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $15.18.

Several analysts have recently issued reports on the stock. Morgan Stanley set a $10.00 target price on shares of Arvinas in a research note on Monday, August 10th. Evercore set a $14.00 price target on shares of Arvinas in a research report on Monday, August 10th. Wells Fargo & Company cut shares of Arvinas from an “overweight” rating to an “equal weight” rating and cut their price target for the stock from $15.00 to $11.00 in a report on Tuesday, August 4th. BTIG Research restated a “buy” rating and set a $18.00 price target on shares of Arvinas in a report on Tuesday, August 4th. Finally, Wedbush upped their price objective on shares of Arvinas from $11.00 to $12.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 5th.

Hedge Funds Weigh In On Arvinas

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Bank of America Corp DE bought a new stake in shares of Arvinas during the 2nd quarter worth $2,102,000. Man Group plc purchased a new position in shares of Arvinas in the 2nd quarter worth about $2,128,000. GSA Capital Partners LLP purchased a new position in shares of Arvinas in the 2nd quarter worth about $1,182,000. Squarepoint Ops LLC grew its position in Arvinas by 760.3% during the second quarter. Squarepoint Ops LLC now owns 201,822 shares of the company’s stock valued at $1,677,000 after buying an additional 178,362 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new position in Arvinas during the second quarter valued at about $1,388,000. Hedge funds and other institutional investors own 95.19% of the company’s stock.

Key Stories Impacting Arvinas

Here are the key news stories impacting Arvinas this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $13 price target, well above the recent share price. The firm’s rating is supportive, though its newly issued forecasts anticipate losses in several future periods. Arvinas Stock Picked Up by Analysts at HC Wainwright
• Neutral Sentiment: Arvinas plans to present preliminary Phase 1 data for ARV-393, its investigational BCL6 degrader, at the 2026 American Society of Hematology meeting. The update could provide a clinical catalyst, but the announcement itself does not include trial results. Arvinas to Present Preliminary Clinical Data for ARV-393
• Negative Sentiment: HC Wainwright’s estimates project losses of $2.44 per share in 2027 and $2.70 in 2028, followed by further losses through 2030. Those forecasts highlight the risk of extended unprofitability and may weigh on sentiment despite the firm’s Buy rating. Arvinas Stock Picked Up by Analysts at HC Wainwright

Arvinas Stock Performance

Shares of Arvinas stock opened at $6.41 on Monday. The company has a market capitalization of $419.79 million, a P/E ratio of -26.71 and a beta of 1.81. The stock has a fifty day simple moving average of $7.86 and a 200 day simple moving average of $9.57. Arvinas has a 12-month low of $6.38 and a 12-month high of $14.51.

Arvinas (NASDAQ:ARVN) last issued its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.82) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.10. The business had revenue of $0.50 million for the quarter, compared to analysts’ expectations of $12.39 million. Arvinas had a negative return on equity of 2.00% and a negative net margin of 3.45%. The business’s revenue was down 98.8% on a year-over-year basis. During the same period last year, the business earned ($0.48) EPS. On average, analysts predict that Arvinas will post 0.18 EPS for the current year.

About Arvinas

Arvinas, Inc is a clinical-stage biopharmaceutical company focused on developing medicines based on targeted protein degradation. The company’s proprietary PROTAC® protein degrader platform is designed to direct the body’s natural cellular machinery to selectively break down disease-causing proteins that may be difficult to address with conventional drug approaches.

Arvinas has concentrated its research and development efforts primarily on oncology, including hormone-driven cancers. Its pipeline has included vepdegestrant, an estrogen receptor protein degrader being developed for patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer, as well as other investigational degraders targeting cancer-related proteins.